GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

Less than six months into the $1.9 billion acquisition of Sierra Oncology, GSK has started to explore the possibility of new indications for the deal centerpiece, JAK inhibitor momelotinib.